You are in:Home/Publications/EFFECT OF ADDING RECOMBINANT ERYTHROPOIETIN TO IRON SUCROSE IN TREATMENT OF SEVERE ANEMIA IN SECOND HALF OF PREGNANCY: A RANDOMIZED CLINICAL TRIAL

Dr. Amr ali mohamed shrafeldien :: Publications:

Title:
EFFECT OF ADDING RECOMBINANT ERYTHROPOIETIN TO IRON SUCROSE IN TREATMENT OF SEVERE ANEMIA IN SECOND HALF OF PREGNANCY: A RANDOMIZED CLINICAL TRIAL
Authors: Amr Sharafeldeen
Year: 2018
Keywords: Not Available
Journal: Not Available
Volume: Not Available
Issue: Not Available
Pages: Not Available
Publisher: Not Available
Local/International: International
Paper Link: Not Available
Full paper Amr ali mohamed shrafeldien_1.pdf
Supplementary materials Not Available
Abstract:

The aim of this trial was to evaluate the effectiveness and safety of intravenous infusion (IV) of iron su- crose (IS) with adjuvant recombinant human erythropoietin (rhEpo) versus Intravenous Iron sucrose alone in treating severe iron deficiency anemia (IDA) in second half of pregnancy. Patients and Methods: Seventy two pregnant women with gestational age ³ 20 week with severe IDA resistant to oral iron treatment were randomly allocated to IS+ group, where women received 200 mg iron sucrose intrave- nously in 50 ml 0.9% saline directly three times per week and after 1st week rhEpo subcutaneously was add- ed at each iron treat visit at 4000 u dose and to IS – group, when women only received intravenous iron sucrose in the some prior fashion, the target hemoglobin was 11 gm /dl. The main outcomes were hematological respond to treatment as increase in hemoglobin (Hg), Hematocrite % (hct) and reticu- locytic count% (RC) while the second- ary outcomes were other hematologi- cal response parameters, serum ferri- tin, patients anemia related symptoms, side effects of treatment. Results: Both treatment regimens were safe and effective in treating se- vere gestational IDA but the change in hematological parameters at follow up period 8, 15, 22, 43 day were signifi- cantly in favor adding rhEpo to IS including reticelocytic count (P < 0.05), hemoglobin (P < 0.05), rising of hematocrit % (P < 0.05). Also the im- provement of anemia related symp- toms with in favor of adding rhEpo to IS at 8, 15, 43 day P < 0.05). At the end of the trial (day 43) more women in IS+ group reach target HB of 11 mg/ dl, the women didn't reach target HB of 11gm/dl were (2/30 (6.6%) in IS+ versus 8/29 (27.5%) in IS-, P = 0.02). There was no difference as regards serum ferritin as well as maternal and fetal safety outcomes parameters. Conclusion: Intravenous iron sucrose 200 mg in 50 ml 0.9% saline given in- travenous day after day with adding subcutaneous recombinant women erythropoietin (4000 u) in the second week after replenish the iron stores safely synergistic the efficacy of the iron sucrose regimen in correcting severe iron deficiency anemia in se- cond half of pregnancy which failed to be treated with oral iron.

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus